Tanding

Quick links to important sections

Tanding

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tanding

What Type of Medicine is Tanding (Nitrofurantoin)?

Tanding is a pharmaceutical preparation belonging to the antibacterial agent class of medicines, specifically known as a synthetic nitrofuran antibiotic. Its sole active ingredient is Nitrofurantoin. This substance is clinically utilized for its specialized role as a urinary tract antiseptic, differentiating its use from many systemic antibiotics. Nitrofurantoin is primarily used to manage and prevent urinary tract infections, providing a targeted anti-infective treatment compared to broader-scope medications.


Composition, Origin, and Forms of Tanding

The composition of Tanding is centered on Nitrofurantoin, a compound chemically categorized as a synthetic nitrofuran derivative. This means the drug is formulated in a laboratory setting to ensure controlled purity. It is manufactured as a single-ingredient product and is available for the oral route of administration in various dosage forms. These typically include the tablet and the capsule, sometimes utilizing a specialized monohydrate/macrocrystals formulation. This macrocrystalline form is a differentiating factor designed for a slower release compared to standard forms, which is intended to improve patient tolerance.


General Purpose and Targeted Action

The general purpose of this medicine is to combat and clear bacterial presence through its anti-infective action concentrated in the urinary tract. The drug operates by achieving high concentrations directly in the urine after consumption. This targeted approach ensures the medicine's activity is concentrated where the infection is typically located. This accumulation of the active ingredient at the site of infection facilitates localized anti-bacterial action. This process provides a method for disrupting bacterial viability and supporting the restoration of a healthy state within the urinary system.

Regulatory References

  1. Nitrofurantoin - StatPearls - NCBI Bookshelf

What side effects are possible with Tanding?

Possible Side Effects and Safety Information

Regulatory safety information for Tanding (Nitrofurantoin) outlines adverse reactions grouped by frequency and affected body systems, focusing on maintaining a clear, non-instructional profile consistent with official labels.


Adverse Reaction Classification

Adverse reactions are primarily classified into Common effects, often affecting the gastrointestinal tract, and Rare events concerning the pulmonary, hepatic, and nervous systems. Many serious reactions are listed as Frequency Not Known due to limitations in data estimation.

Classification Common Examples (SOC)
Common Nausea, Vomiting, Diarrhea (Gastrointestinal); Headache (Nervous System)
Rare Cholestatic Jaundice, Chronic Active Hepatitis (Hepato-biliary); Peripheral Neuropathy (Nervous System)

Serious Adverse Reactions and Safety Patterns

The official safety profile highlights potentially severe or fatal reactions, including Peripheral Neuropathy (which may become irreversible), Acute and Chronic Pulmonary Reactions, and Hepatotoxicity (e.g., hepatic necrosis). These are associated with specific time patterns:

  • Acute Pulmonary Reactions typically occur within the first week of treatment.
  • Chronic Pulmonary Reactions and the risk of Peripheral Neuropathy are primarily associated with prolonged use, generally six months or longer.

Population-Specific Safety Restrictions

Specific safety restrictions are documented in regulatory labels for certain patient groups:

  • The drug is contraindicated in patients with significant Renal Impairment (creatinine clearance typically below 60 mL/minute).
  • It is also contraindicated in term pregnancy and in neonates under one month of age due to the risk of haemolytic anaemia, a risk also noted in individuals with G6PD deficiency.

This structure defines the drug's safety boundaries by defining risk based on frequency, system affected, duration of exposure, and patient characteristics.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory documents confirm that management of Nitrofurantoin overdose relies solely on symptomatic treatment and supportive measures, as no specific antidote is known. Acute overdose is most likely to manifest as nausea and vomiting.

Severe Outcomes and Mandatory Action

Overdose or toxicity, which can be heightened in scenarios of impaired drug clearance, may lead to severe, potentially irreversible outcomes. These include peripheral neuropathy, hepatic necrosis, and pulmonary fibrosis, with fatalities having been reported in association with these severe reactions affecting the neurological, hepatic, and pulmonary systems.

The official regulatory requirement is to seek immediate medical attention for signs of severe systemic reactions, collapse, seizure, or severe difficulty breathing. Furthermore, the medication must be discontinued immediately at the first signs of toxicity, such as tingling in the extremities (paresthesia) or symptoms of liver or lung injury, to halt the progression toward irreversible damage.

Management and Special Considerations

For recent large ingestions, procedural measures such as gastric lavage or administering activated charcoal should be considered. Monitoring of the patient’s full blood count and liver and pulmonary function is recommended. Patients with impaired renal function are at a documented increased risk of toxicity due to reduced drug clearance.

Therapeutic Uses of Tanding

Tanding is a medication intended to help manage symptoms associated with common ailments. Its purpose is to provide symptom relief, which can be supportive in various short-term care scenarios.

The medication is used to address symptoms from conditions such as mild to moderate pain (including headaches and muscle aches), fever, and specific symptoms related to colds and flu. These are typically seen in general practice for temporary symptomatic care. Patients may find the reduction of discomfort supportive of rest and daily activities while the underlying condition is addressed.

Quick Fact: Relief for Fever and Mild to Moderate Pain

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Tanding (Nitrofurantoin) eligibility is determined strictly by regulatory guidelines established by health authorities. The medicine is contraindicated and must not be used in several populations. Absolute non-eligibility applies to patients with a known hypersensitivity to the drug or other nitrofuran derivatives.

Use is strictly prohibited in patients with significant impairment of renal function, typically defined by a creatinine clearance under 60 mL per minute or an estimated glomerular filtration rate (eGFR) less than 45 mL/minute/1.73m².

Age-related restrictions dictate that Tanding is contraindicated in neonates under one month of age. Furthermore, the drug is contraindicated for pregnant patients at term (near labor/delivery) due to specific risks to the neonate. The medicine is generally approved for adults and pediatric patients one month of age and older.

Use is not recommended or requires caution in specific circumstances, including breastfeeding mothers of infants under one month old or those with Glucose-6-phosphate dehydrogenase (G6PD) deficiency. Caution is also required in older adults and patients with debilitating conditions such as diabetes mellitus or a prior history of cholestatic jaundice associated with nitrofurantoin.

What should I know about interactions with other medicines?

Tanding (Nitrofurantoin) has documented interactions that primarily affect its exposure and anti-infective efficacy, as described in official prescribing information.

The co-administration of uricosuric agents such as Probenecid or Sulfinpyrazone is known to inhibit the drug's renal tubular secretion. This pharmacokinetic mechanism results in a reduced concentration of Tanding in the urine, potentially diminishing its antibacterial efficacy, while simultaneously causing an increase in its systemic serum levels and potential for toxicity.

A second pharmacokinetic interaction occurs with antacids containing Magnesium Trisilicate, which formally reduce both the rate and extent of Tanding's absorption. Regulatory documents specify that these antacids must not be used concomitantly to prevent loss of therapeutic effect.

A pharmacodynamic antagonism has been observed in vitro between Tanding and quinolone antimicrobial agents; however, the clinical significance of this finding is officially stated as unknown. Tanding may also reduce the effectiveness of the oral typhoid vaccine (live). For oral administration, taking Tanding with food is documented to increase its bioavailability, which prolongs the presence of effective concentrations in the urine.

Additionally, a specific interaction with laboratory tests exists, causing a false-positive reaction for glucose in the urine when tested with Benedict's or Fehling's solutions. A separate population-specific consideration noted in the label is the increased risk of hemolytic anemia when Tanding is administered to individuals with Glucose-6-Phosphate Dehydrogenase (G-6-PD) deficiency.

Mechanism of Action

How Tanding Works: Mechanism of Action

The drug's activity is initiated by a specific process of intracellular bio-activation within the bacterial cell. This complex mechanism is defined by the drug's conversion into a toxic intermediate and the resulting multi-target damage.

Enzymatic Bio-activation and Toxic Intermediates

The primary biological targets are the bacterial nitroreductase enzymes (flavoproteins) found inside susceptible cells. These enzymes reduce the compound, initiating a cascade that produces highly reactive nitrofurantoin radicals and Reactive Oxygen Species (ROS). This initial molecular event results in the compound's action being preferentially localized to the pathogen over host tissues, and this activation step is required for the subsequent destructive effect.

Non-Specific Macromolecular Damage

The highly reactive intermediates immediately and indiscriminately bind to key bacterial macromolecules, including DNA, RNA, and ribosomal proteins. This multi-target assault simultaneously interrupts the cell's ability to replicate its genome and synthesize new proteins, while also disrupting essential energy and metabolic pathways. The resulting widespread cellular damage leads to immediate bacterial cytotoxicity and the cessation of replication.

Constraints on Mechanistic Efficacy

The action is entirely constrained by the presence of the activating nitroreductase enzymes. The mechanism is thus fundamentally limited against bacterial strains that have mutations preventing this enzymatic reduction or against organisms that are intrinsically resistant because they lack the necessary internal machinery, preventing the mechanistic cascade from proceeding.

Dosage and Administration Information

Tanding is an antibacterial agent approved solely for oral administration. The specific administration schedule depends directly on the dosage form utilized. For the treatment of acute, uncomplicated infections, standard-release formulations are typically taken in doses of 50 mg to 100 mg four times daily (QID). In contrast, the prolonged-release capsule formulation is administered at 100 mg twice daily (BID), a pattern designed to maintain consistent drug concentration.

A core requirement for proper use is that the medication must be consumed with food or milk. This instruction is specified to enhance the drug's absorption and improve its overall tolerability within the gastrointestinal tract. The duration of use is dictated by the treatment goal: acute infections are generally treated for a short, seven-day course, while long-term suppressive use may extend for up to 12 months to prevent recurrence.

Specific procedural rules govern different preparations. The oral suspension, often used for pediatric dosing, must be shaken vigorously before measurement. Furthermore, the prolonged-release capsule must always be swallowed whole and must not be crushed or chewed, as doing so compromises its intended slow-release characteristic. For children aged one month and older, the acute dosage is calculated based on body weight, typically 5 mg/kg to 7 mg/kg per day, divided into four separate doses. If a dose is missed, it should be skipped if the next dose is almost due, and the dose should never be doubled.

Recent Clinical Evidence

Tanding: Recent Clinical Evidence

The following summary provides an overview of how Tanding has been investigated in clinical and preclinical settings. It strictly describes what was evaluated in research and does not offer medical advice or conclusions regarding treatment suitability.


Research on Chronic Pain Management

Research has explored the role of this agent in studies related to pain associated with conditions such as chronic back pain and osteoarthritis.

  • Mechanism of Action: Mechanistic research has focused on the inhibition of key inflammatory pathways. Studies have examined whether this action is associated with a reduction in reported pain.
  • Clinical Trial Findings: Early-phase clinical trials evaluated the agent’s potential for use in a range of inflammatory conditions. Subsequent Phase 3 trials have concentrated on long-term outcomes and assessment of tolerability.
  • Dose Response: Research protocols utilized varied dosage regimens for evaluation of efficacy and tolerability.

Specific Outcomes Evaluated in Research

Outcome Area Outcome Measure Evaluated
Joint Function and Mobility Changes in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score after 12 weeks of assessment.
Combination Therapy Change in the Visual Analog Scale (VAS) score for pain when the agent was used alongside standardized physiotherapy.
Comparative Studies Outcomes related to the comparison agent (Diclofenac) in a non-inferiority trial involving n=450 subjects.

Some studies reported findings related to joint function and mobility; however, the results across different trials were mixed. In studies evaluating the agent alongside physiotherapy, results varied across the different patient subgroups evaluated. Evidence remains limited on long-term comparative findings against other common treatments.

Key Studies & References Meta-analysis of four randomized trials assessing Tanding in chronic arthritis (WOMAC outcomes)

Frequently Asked Questions (FAQ)

Common questions about Tanding (FAQ)


Q: Is Tanding a maintenance drug or used for acute symptoms?

Official information indicates that Tanding has approved uses for both the treatment of acute infections and for long-term prophylaxis to help prevent infections from recurring. The treatment duration is determined by the specific goal outlined in the regulatory indications.


Q: Does Tanding typically cause fatigue or drowsiness?

According to regulatory documents, effects on the nervous system are possible with Tanding. Side effects such as dizziness, drowsiness, weakness, and fatigue have been reported in official labeling. Patients experiencing these effects should exercise caution when performing activities that require alertness, such as driving or operating machinery.


Q: Can Tanding affect mood or sleep patterns?

Official product information notes central nervous system effects, including dizziness and drowsiness. While the label does not specifically detail effects on general mood or long-term sleep patterns, patients are advised to observe and report any changes in their usual state.


Q: Can Tanding be taken with common pain relievers?

Regulatory guidance states that common, non-prescription pain relievers such as acetaminophen (paracetamol) and ibuprofen are not known to have direct interactions with Tanding. It is standard safety practice to review all medications, including over-the-counter drugs, with a healthcare professional.


Q: Does Tanding interact with blood pressure medication?

Official interaction warnings list specific drugs like uricosuric agents, which are sometimes used to treat gout and can affect kidney function. The label does not list general blood pressure medication classes as a commonly reported interaction.


Q: Are there any known food or drink restrictions when taking Tanding?

Official administration instructions require Tanding to be consumed with food or milk. This instruction helps optimize absorption and reduce potential gastrointestinal discomfort. Additionally, antacids containing the specific ingredient magnesium trisilicate are contraindicated and must not be taken at the same time.


Q: Does alcohol interact with Tanding?

There is no widely known direct interaction between Tanding and alcohol described in official documents. However, general patient information often advises limiting or avoiding alcohol, as it can be a bladder irritant and may worsen symptoms of the underlying infection being treated.


Q: How long does it usually take to feel the effects of Tanding?

Studies and official information indicate that the medication begins working in the body within a few hours of the first dose. Noticeable improvement in symptoms is generally expected within a few days of starting the full course of treatment.


Q: Is Tanding suitable for older adults (seniors)?

Official safety restrictions require that Tanding be used with caution in older adults. This is because this population may have an increased risk of side effects, particularly if they have underlying conditions that affect kidney function, which is a major factor in the drug’s clearance.


Q: Can people with kidney problems use Tanding?

Tanding is contraindicated, meaning its use is prohibited for individuals who have significant impairment of renal (kidney) function. This restriction is in place because reduced kidney function can prevent the drug from being concentrated in the urine, and it can increase the risk of toxicity in the body.


Q: What type of research evidence supports the use of Tanding?

The approved use of Tanding is supported by data gathered from clinical trials. This research confirmed the medication's effectiveness in treating and preventing bacterial infections, specifically those located in the urinary tract.


Q: What stage of clinical trials did Tanding go through before approval?

Like all prescription drugs, Tanding went through a rigorous process of clinical trials that included various phases. These studies collected data to confirm the drug’s efficacy (how well it works), its safety profile, and its optimal dosing regimens before it received regulatory approval.


Q: Is Tanding similar to a steroid or an opioid?

Official documents classify Tanding as a nitrofuran antibacterial agent. This classification means the medication works specifically to fight bacteria and is not chemically related to or classified as either a steroid or an opioid.


Q: If I feel better, is it normal to stop taking Tanding?

Official patient information advises patients to complete the full prescribed course of Tanding. Stopping the treatment early, even if symptoms improve, is generally warned against as it may allow the underlying infection to return or be improperly treated.


Q: Is it true that Tanding needs to be taken at the exact same time every day?

Official administration guidance advises patients to space their doses as evenly as possible throughout the day. This helps ensure that a consistent concentration of the drug is maintained to fight the infection effectively.


Q: What should I do if I get an allergic reaction to Tanding?

If signs of a serious allergic reaction occur, such as swelling of the face, difficulty breathing, or a rash accompanied by blistering, immediate emergency medical attention is necessary. Hypersensitivity to Tanding is a contraindication to its use.


Q: Does Tanding affect liver enzymes?

Due to the potential risk of liver injury (hepatotoxicity), official guidance advises periodic monitoring of patients through biochemical tests. This monitoring can detect changes in liver enzymes or function, especially during long-term use.


Q: Why is the maximum recommended usage period for Tanding limited?

The usage period for Tanding is limited because official warnings indicate that prolonged treatment carries an increased risk of severe, potentially irreversible adverse effects. These risks include serious chronic reactions affecting the lungs and damage to the peripheral nerves (peripheral neuropathy).


Q: What official warnings are there about stopping Tanding suddenly?

Official patient information advises against stopping the medication suddenly. Patients are generally advised to complete the entire course as prescribed to ensure the infection is fully eliminated and to prevent recurrence.


Q: How does the regulatory body (e.g., FDA) describe Tanding’s mechanism of action?

Regulatory documents describe the drug's mechanism of action as involving a complex process where bacterial enzymes reduce the medication into highly reactive intermediate compounds. These compounds then damage essential bacterial components, such as proteins, DNA, and RNA, leading to the death of the cell.


Q: Is it possible to develop a rash while taking Tanding?

Rashes, hives, and other hypersensitivity reactions are reported adverse effects of Tanding. Official safety information also notes the possibility of developing rare, serious skin reactions that may involve blistering or peeling.


Q: Does Tanding interact with birth control pills?

Official information states that Tanding is not known to directly alter the effectiveness of oral contraceptive pills. However, if the medication causes side effects like severe vomiting or diarrhea, the ability of the birth control pill to work may be reduced due to poor absorption.


Q: Where does Tanding fit in the treatment path for the condition it treats?

Clinical practice guidelines recognize Tanding as one of the first-line treatment options for patients diagnosed with acute, uncomplicated urinary tract infections (UTIs). Its specialized action targeting the urinary tract makes it a preferred option in specific clinical scenarios.

How should Tanding be stored and disposed of?

Official Storage and Disposal Requirements

Storage of Tanding (nitrofurantoin) must adhere strictly to the regulatory instructions provided in the official product labeling to maintain stability.

Storage Domain Regulatory Requirement
Temperature & Protection Store at Controlled Room Temperature, typically 20 C to 25 C. The product must be protected from light and moisture, and the oral suspension is instructed not to be frozen.
Packaging & Safety Keep the medicine in its original container and ensure it is tightly closed. The product must be stored out of the sight and reach of children.
Stability Period The oral suspension must be discarded after 30 days of reconstitution and typically requires refrigeration during this period.
Disposal Do not flush unused or expired medicine down a drain. Follow official guidelines by returning it to a medicine take-back program or disposing of it according to specific trash disposal instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tanding found in:

A-Z Index: